31 Mar 2020

U.S. TAXPAYERS PAID MILLIONS TO DESIGN A LOW-COST VENTILATOR FOR A PANDEMIC: INSTEAD, A ROYAL PHILIPS N.V. SUBSIDIARY IS SELLING VERSIONS OF IT OVERSEAS.

    By Patricia Callahan, Sebastian Rotella and Tim Golden ProPublica   Five years ago, the U.S. Department of Health and Human Services tried to plug a crucial hole in its preparations for a global pandemic, signing a $13.8 million contract with a Pennsylvania manufacturer to create a low-cost, portable, easy-to-use ventilator that

0
28 Mar 2020

MEDTRONIC FOUNDATION GIVES $10 MILLION MORE TO COVID-19 EFFORTS

  The Medtronic  Foundation is making an additional $10 million in contributions to COVID-19 relief efforts around the world. The Fridley, Minn.-based company spokesman said that the funds will be put toward training and supervising frontline health workers, ensuring their safety (including the provision of personal protective equipmonprofit partners working

0
18 Feb 2020

GEOFF MARTHA TO REPLACE OMAR ISHRAK AT MEDTRONIC APRIL 27

       Geoff Martha, who leads Medtronic’s restorative therapies group and previously oversaw the company’s spine business, will succeed Omar Ishrak as president and CEO on April 27. Ishrak ‘s nearly 10-year tenure as chairman and CEO of Medtronic will come to an end when he retires April 26.

0
12 Feb 2020

MEDTRONIC AND THE MEDTRONIC FOUNDATION COMMIT MORE THAN $1M TO CORONAVIRUS EFFORTS

    Medtronic plc  and the Medtronic Foundation are committing approximately $1.2 million to coronavirus relief efforts across the globe. These contributions encompass Medtronic Foundation cash contributions and product donations from the company, according to an announcement Feb. 10.                Medtronic Foundation is partnering

0
26 Jun 2019

CHARING CROSS 2019: MEDTRONIC EXPANDS ON KEY AORTIC SOLUTIONS FOR CHALLENGING ANATOMIES

  Medtronic plc released new data on endovascular repair of abdominal aortic aneurysm (AAA) patients with the Endurant II/IIs stent graft system in combination with Heli-FX EndoAnchor implants and for the Valiant Navion thoracic stent graft system for thoracic endovascular repair (TEVAR). The data, which was presented at the Charing Cross

0
12 Jun 2019

VECLOSE EXTENSION STUDY: Five-year outcomes prove durability, safety, efficacy of VenaSeal Closure System

    By Larry Storer Five-year results from the 2019 VeClose Extension Study of the Medtronic VenaSeal Closure System demonstrate that the treatment modality is consistent, durable and safe for permanently closing veins in patients with venous reflux disease. When compared with Medtronic Radiofrequency Ablation, VenaSeal continued to show “non-inferiority”

0
09 May 2019

Government policy shift prompts Medtronic to bail on bundled knees; Responsive Orthopedics for sale

After three years in the bundled joint replacement business, a federal policy shift is prompting Medtronic to put its Responsive Orthopedics business on the auction block. The May 2016 acquisition of Minneapolis-based Responsive for an undisclosed amount put Medtronic in line for a bundled joint replacement program piloted by the Centers for Medicare & Medicaid Services. The 5-year “Comprehensive

0
28 Mar 2019

A NEW RF SYSTEM: VENCLOSE 2ND GENERATION RADIOFREQUENCY TECHNOLOGY OUTPERFORMS LEGACY SYSTEM

    By Larry Storer The great medical technology companies of our time start and develop in a variety of ways. Some start with a product or idea and built a market around it. Some start as spinoffs from existing successful companies. But Venclose started by determining the unmet needs

0
28 Mar 2019

FDA evaluating stents, balloons with paclitaxel coating following JAHA evaluation

A December study in The Journal of the American Heart Association by Konstantinos Katsanos, MD, of Rion, Greece, et al, reported a higher risk of death after balloons and stents used to open vessels in the legs were coated with an anti-inflammatory chemo agent called paclitaxel. “Further investigations are urgently

0
28 Mar 2019

Judge accepts Medtronic plea settling ev3 case

A federal judge in Boston accepted a plea deal from Medtronic neurovascular subsidiary ev3 in an off-label marketing case, according to court documents released at the end of January. U.S. Magistrate Judge Judith Dein granted the motion, which included the forfeiture of $6 million and an additional $11.9 million in

0